Penn Engineers Develop More Effective MRI Contrast Agent for Cancer Detection
Many imaging technologies and their contrast agents — chemicals used during scans to help detect tumors and other problems — involve exposure to radiation or heavy metals, which present potential health risks to patients and limit the ways they can be applied. In an effort to mitigate these drawbacks, new research from University of Pennsylvania engineers shows a way to coat an iron-based contrast agent so that it only interacts with the acidic environment of tumors, making it safer, cheaper and more effective than existing alternatives.
The research was conducted by associate professor Andrew Tsourkas and graduate student Samuel H. Crayton of the department of bioengineering in Penn’s School of Engineering and Applied Science. It was published in the journal ACS Nano.
Magnetic resonance imaging, or MRI, is an increasingly common feature of medical care. Using a strong magnetic field to detect and influence the alignment of water molecules in the body, MRI can quickly produce pictures of wide range of bodily tissues, though the clarity of these pictures is sometimes insufficient for diagnoses. To improve the differentiation — or contrast — between tumors and healthy tissue, doctors can apply a contrast agent, such as nanoparticles containing iron oxide. The iron oxide can improve MRI images due to their ability to distort the magnetic field of the scanner; areas they are concentrated in stand out more clearly.
These nanoparticles, which have recently been approved in the United States for clinical use as contrast agents, are literally sugar-coated; an outer layer of dextran keeps the particles from binding or being absorbed by the body and potentially sickening the patient. This non-reactive coating allows the iron oxide to be flushed out after the imaging is complete, but it also means that the particles can’t be targeted to a particular kind of tissue.
If the contrast agent could be engineered so it only sticks to tissue that is already diseased, such as tumors, it would solve both problems at once. Scientists have tried this approach by coating nanoparticles with proteins that bind only to receptors found on the exterior of tumors, but not all tumors are the same in this regard.
“One of the limitations of a receptor-based approach is that you just don’t hit everything,” Tsourkas said. “It’s hard to recommend them as a screening tool when you know that the target receptors are only expressed in 30% of tumors.”
“One of the reasons we like our approach is that it hits a lot of tumors; almost all tumors exhibit a change in the acidity of their microenvironment.”
The Penn engineers took advantage of something known as the Warburg effect, a quirk of tumor metabolism, to get around the targeting problem. Most of the body’s cells are aerobic; they primarily get their energy from oxygen. However, even when oxygen is plentiful, cancerous cells use an anaerobic process for their energy. Like overtaxed muscles, they turn glucose into lactic acid, but unlike normal muscles, tumors disrupt the blood flow around them and have a hard time clearing this acid away. This means that tumors almost always have a lower pH than surrounding healthy tissue.
Some imaging technologies, such as magnetic resonance spectroscopy, can also take advantage of tumors’ low-pH microenvironments, but they require expensive specialized equipment that is not available in most clinical settings.
By using glycol chitosan — a sugar-based polymer that reacts to acids — the engineers allowed the nanocarriers to remain neutral when near healthy tissue, but to become ionized in low pH. The change in charge that occurs in the vicinity of acidic tumors causes the nanocarriers to be attracted to and retained at those sites.
This approach has another benefit: the more malignant a tumor is, the more it disrupts surrounding blood vessels and the more acidic its environment becomes. This means that the glycol chitosan-coated is a good detector of malignancy, opening up treatment options above and beyond diagnosis.
“You can take any nanoparticle and put this coating on it, so it’s not limited to imaging by any means,” said Tsourkas. “You could also use it to deliver drugs to tumor sites.”
The researchers hope that, within seven to 10 years, glycol-chitosan-coated iron oxide nanoparticles could improve the specificity of diagnostic screening. The ability to accurately detect sites of malignancy by MRI would be an immediate improvement to existing contrast agents for certain breast cancer scans.
“Gadolinium is used as a contrast agent in MRI breast cancer screenings for high-risk patients. These patients are recommended to get an MRI in addition to the usual mammogram, because the sensitivity of mammograms can be poor,” said Tsourkas. “The sensitivity of an MRI is much higher, but the specificity is low: the screening detects a lot of tumors, but many of them are benign. Having a tool like ours would allow clinicians to better differentiate the benign and malignant tumors, especially since there has been shown to be a correlation between malignancy and pH.”
The research was supported by the National Institutes of Health and the Department of Defense Breast Cancer Research Program.